# A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy

> **NCT02670044** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 88 (actual)

## Conditions studied

- Leukemia, Myeloid, Acute

## Interventions

- **DRUG:** Cobimetinib
- **DRUG:** Idasanutlin
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT02670044
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-09
- **Primary completion:** 2020-12-10
- **Final completion:** 2020-12-10
- **Target enrollment:** 88 (ACTUAL)
- **Last updated:** 2022-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02670044

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02670044, "A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02670044. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*